MANNKIND CORP Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Instruments Classified in Shareholders' Equity, Transfers Into Level 3 (Deprecated 2019-01-31)
MANNKIND CORP (MNKD) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Instruments Classified in Shareholders' Equity, Transfers Into Level 3 (Deprecated 2019-01-31) of $1.08 million for the 9-month period ending 2012-09-30, per its 10-Q filed 2012-11-09.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityTransfersIntoLevel3 · last filed 2013-05-10
- MANNKIND CORP fair value, measurement with unobservable inputs reconciliation, recurring basis, instruments classified in shareholders' equity, transfers into level 3 (deprecated 2019-01-31) for the quarter ending 2012-03-31 was $1.08M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Instruments Classified in Shareholders' Equity, Transfers Into Level 3 (Deprecated 2019-01-31) 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Instruments Classified in Shareholders' Equity, Transfers Into Level 3 (Deprecated 2019-01-31) 9 month |
|---|---|---|
| 2012-09-30 | $1.08M 10-Q · filed 2012-11-09 | |
| 2012-03-31 | $1.08M 10-Q · filed 2013-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |